Discovery of the First in Vivo Active Inhibitors of the Soluble Epoxide Hydrolase Phosphatase Domain
作者:Jan S. Kramer、Stefano Woltersdorf、Thomas Duflot、Kerstin Hiesinger、Felix F. Lillich、Felix Knöll、Sandra K. Wittmann、Franca-M. Klingler、Steffen Brunst、Apirat Chaikuad、Christophe Morisseau、Bruce D. Hammock、Carola Buccellati、Angelo Sala、G. Enrico Rovati、Matthieu Leuillier、Sylvain Fraineau、Julie Rondeaux、Victor Hernandez-Olmos、Jan Heering、Daniel Merk、Denys Pogoryelov、Dieter Steinhilber、Stefan Knapp、Jeremy Bellien、Ewgenij Proschak
DOI:10.1021/acs.jmedchem.9b00445
日期:2019.9.26
pharmacological target solubleepoxidehydrolase (sEH) is a bifunctional enzyme exhibiting two different catalytic activities that are located in two distinct domains. Although the physiological role of the C-terminal hydrolase domain is well-investigated, little is known about its phosphatase activity, located in the N-terminal phosphatase domain of sEH (sEH-P). Herein we report the discovery and optimization
申请人:Merck Patent Gesellschaft mit beschrankter Haftung
公开号:US04051250A1
公开(公告)日:1977-09-27
Azole derivatives of the formula ##STR1## wherein R.sub.1 is free or esterified carboxyl or other functionally modified carboxyl group, R.sub.2 and R.sub.3 each are aryl; A is C.sub.n H.sub.2n in which n is an integer from 1 to 10, inclusive; and Z is O or S; and the physiologically acceptable salts thereof, possess, with good compatibility, excellent antiphlogistic activity and, in particular, influence favorably the chronic progressive diseases of the joints, e.g., arthritis. They can be prepared from compounds of the formula ##STR2## wherein X.sub.1 is a group convertible into the group --S--A--R.sub.1, and R.sub.2 and R.sub.3 have the values given above.